STAT+: Pharmalittle: We’re reading about Novo plans to expand its pipeline, early Alkermes ADHD data, and more
Hello there and welcome to a new week. STAT reporter Andrew Joseph here in London filling in for Mr. Pharmalot for the day. Before we get to the headlines, an extra dose of encouragement to check out all the great pieces that STAT has to offer today, from Reed Jobs opining on the NIH budget to our new trust-in-science reporter Nick Florko outlining his own experience grappling with, as he puts it, “how frustrating it is to realize that modern medicine does not have all the answers.” Now to those headlines. …
Novo Nordisk is seeking to assure investors that it can regain its momentum in the coming years, outlining plans to expand its pipeline and find new products that it could sell more like consumer goods than traditional medicines, building off what’s occurring with its obesity treatments, STAT shares. At the company’s capital markets day in London, CEO Mike Doustdar said Novo would launch at least five multi-blockbusters by 2030 and deliver revenue growth on par with other major pharma firms. He also presented a strategy that involved investing more in disease areas outside diabetes and obesity and said the company “will be more active within business development,” an acknowledgment of investors’ concerns that Novo was too reliant on its landmark GLP-1 drugs and needed to develop other products.
Drugs called orexin agonists have been hailed for their ability to treat rare sleep disorders, but with new data, Alkermes is showing for the first time that the new class of therapies may benefit people with ADHD, STAT writes. In a randomized Phase 1 study, the company’s new drug, called ALKS 7290, was well tolerated and showed a signal of efficacy. Participants in the study started with a median score of 39 on a diagnostic known as the Adult ADHD Investigator Symptom Rating Scale, indicating that they had moderate to severe symptoms. After two weeks, those taking a high dose of 50 milligrams of ALKS 7290 experienced a 19-point reduction on the scale, indicating that their symptoms had become mild.
Looking Ahead to the SNF Global Center’s Second Annual Global Summit on Youth Mental Health
By Emma Beckwith, 2026 Youth Mental Health Academy Intern, Child Mind Institute
As mental health care, education, and research for youth advances, it is important to remember that in order to best serve young people, we must listen to their lived experience. They know better than anyone what conversations and changes need to happen to improve child and adolescent mental health care around the world. Therefore, they must be included in this discussion as co-creators and leaders of transformation.
Building on the momentum of last year’s inaugural Global Summit on Youth Mental Health, the Stavros Niarchos Foundation (SNF) Global Center for Child and Adolescent Mental Health at the Child Mind Institute will host the second edition of the annual event on September 21-24 in New York City.

Led by the SNF Global Center’s Global Youth Advisory Council (GYAC), the event is set to unite young people from around the world to discuss the issues impacting their mental health. Additionally, clinicians, researchers, and policymakers will participate in various sessions. The hope is that youth and adult experts can work together to enact necessary changes in child and adolescent mental health care.
The GYAC, consisting of members from the Global Center’s Child and Adolescent Mental Health Initiatives (CAMHI) in Greece, Brazil, and South Africa, took on a leading role in organizing the summit. In every step of the process, they have had input on what they want the summit to look like, new features they want to include, the key topics that will be discussed, as well as the theme for this year’s summit: “Redefining Mental Health Care: Youth Perspectives in a Changing World.” They will also serve as moderators of discussion panels, with each GYAC member leading conversations on topics they feel passionate about.
“Nothing About Us Without Us”
The youth are the present and future and deserve to be the lead contributors in this work. This year, the summit aims to center their voices through three thematic sessions:
- “Meeting Young People Where They Are” will examine how to make school systems safer places for identity expression and mental health education. And they’ll discuss how to make digital spaces safer, including ways to communicate the impact online spaces have on mental wellness to young people.
- “What Young People Care About” will consist of breakout sessions where, in small groups, young people will discuss the modern youth experience in how topics such as climate change, economic instability, and political polarization affect their mental health.
- “Setting Young People Up for the Future” will include a Q&A with experts where youth can learn how to take care of their mental wellness in a changing world.
During last year’s summit, young participants came together to document key takeaways and actionable items for implementation and global change through a published youth-led report. This year, the goal is to increase youth involvement even more, with more youth attendees, speakers, and leaders. After all, this event isn’t just for the betterment of youth and adolescent mental health, but a space for people around the world who have a shared passion and care about this issue to connect and unify in order to enact positive change.
As a young person myself, what I would like to see come out of this year’s summit is action. The event is already an amazing starting point, where both young people and adults have shown their care for improving child and adolescent mental health. Now, we need to take actionable steps to implement the changes needed as voiced by youth, so that the talk doesn’t just stay within the event but becomes a reality. While there is no doubt that it will take time, I have hope that with the continuation of these annual summits, more global experts, changemakers, policymakers, clinicians, researchers, and caretakers will take what they’ve learned into their spaces of work to enact real change.
As Nelly Serdari, a member of the Youth Engagement Scheme (YES) with CAMHI in Greece, stated at last year’s summit, “The only way that we can try to break down barriers is if older generations try to get on our level.”
Now, it is up to the adults to break down the barriers that we youth cannot.
Learn more about the inaugural Global Summit on Youth Mental Heath
Learn more about the Youth Mental Health Academy at the Child Mind Institute
The post Looking Ahead to the SNF Global Center’s Second Annual Global Summit on Youth Mental Health appeared first on Child Mind Institute.
Parental depressive symptoms and shared reading practices among preschool children in western China: cross-sectional study
Body image dissatisfaction and emotional eating across age and weight status: a comparative cross-sectional study
Possible drivers of self-harm severity – relative contributions of post-traumatic stress and levels of personality functioning – results from the Extreme Challenges project
STAT+: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial
Drugs called orexin agonists have been hailed for their ability to treat rare sleep disorders, but with new data, Alkermes is showing for the first time that the new class of therapies may benefit people with ADHD.
In a randomized Phase 1 study, the company’s new drug, called ALKS 7290, was well tolerated and showed a signal of efficacy, Alkermes said Monday.
Participants in the study started with a median score of 39 on a diagnostic known as the Adult ADHD Investigator Symptom Rating Scale, indicating that they had moderate to severe symptoms. After two weeks, those taking a high dose of 50 milligrams of ALKS 7290 experienced a 19-point reduction on the scale, indicating that their symptoms had become mild.
Study on the Prevention of Weight Loss Through Physical Activity Among Nursing Home Residents
Interventions: Other: Physical activity; Other: Appetite assessment; Other: Food intake assessment; Other: Assessment of the efficiency; Biological: Blood test at baseline; Biological: Blood test at the end of the study; Other: Functional capacities assessment; Other: weight measurment
Sponsors: University Hospital, Toulouse
Not yet recruiting
Attachment and Substance Use Disorder: An Interventional Study in an Addictology Day Hospital
Interventions: Behavioral: attachment-focused therapeutic program; Behavioral: psychoeducation-based intervention (standard care)
Sponsors: Centre Hospitalier de Cadillac
Completed

